<!DOCTYPE html>
<html lang="en-us">

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.7.0">

  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Ronald Gangnon">

  
  
  
    
  
  <meta name="description" content="OBJECTIVE:
To describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD). DESIGN:
Multicenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study. PARTICIPANTS:
We enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study. METHODS:
Participants were randomly assigned to antioxidants C, E, and β-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses. MAIN OUTCOME MEASURES:
Photographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (≥15 letters). RESULTS:
Comparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P&lt;0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53-0.83 and OR, 0.60; 95% CI, 0.47-0. 78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71-1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57-0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases. CONCLUSIONS:
Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/pmid-23582353/">

  


  
  
  
  <meta name="theme-color" content="#328cc1">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css" integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=EB+Garamond&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  




  


  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/publication/pmid-23582353/">

  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="Ronald Gangnon">
  <meta property="og:url" content="/publication/pmid-23582353/">
  <meta property="og:title" content="Long-term effects of vitamins C and E, Î²-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 | Ronald Gangnon">
  <meta property="og:description" content="OBJECTIVE:
To describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD). DESIGN:
Multicenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study. PARTICIPANTS:
We enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study. METHODS:
Participants were randomly assigned to antioxidants C, E, and β-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses. MAIN OUTCOME MEASURES:
Photographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (≥15 letters). RESULTS:
Comparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P&lt;0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53-0.83 and OR, 0.60; 95% CI, 0.47-0. 78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71-1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57-0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases. CONCLUSIONS:
Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation."><meta property="og:image" content="img/map[gravatar:%!s(bool=false) shape:circle]">
  <meta property="twitter:image" content="img/map[gravatar:%!s(bool=false) shape:circle]"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2020-02-08T06:30:32&#43;00:00">
    
    <meta property="article:modified_time" content="2013-08-01T00:00:00&#43;00:00">
  

  


    











<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "/publication/pmid-23582353/"
  },
  "headline": "Long-term effects of vitamins C and E, Î²-carotene, and zinc on age-related macular degeneration: AREDS report no. 35",
  
  "datePublished": "2020-02-08T06:30:32Z",
  "dateModified": "2013-08-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "E. Y. Chew"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Ronald Gangnon",
    "logo": {
      "@type": "ImageObject",
      "url": "img//"
    }
  },
  "description": "OBJECTIVE:\nTo describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD). DESIGN:\nMulticenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study. PARTICIPANTS:\nWe enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study. METHODS:\nParticipants were randomly assigned to antioxidants C, E, and β-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses. MAIN OUTCOME MEASURES:\nPhotographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (≥15 letters). RESULTS:\nComparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P\u003c0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53-0.83 and OR, 0.60; 95% CI, 0.47-0. 78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71-1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57-0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases. CONCLUSIONS:\nFive years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation."
}
</script>

  

  


  


  





  <title>Long-term effects of vitamins C and E, Î²-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 | Ronald Gangnon</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">Ronald Gangnon</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">Ronald Gangnon</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#featured"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/files/cv.pdf"><span>CV</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      <li class="nav-item">
        <a class="nav-link js-dark-toggle" href="#"><i class="fas fa-moon" aria-hidden="true"></i></a>
      </li>
      

      

    </ul>

  </div>
</nav>


  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Long-term effects of vitamins C and E, Î²-carotene, and zinc on age-related macular degeneration: AREDS report no. 35</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    



  
  <span>E. Y. Chew</span>, <span>T. E. Clemons</span>, <span>E. Agr?n</span>, <span>R. D. Sperduto</span>, <span>J. P. Sangiovanni</span>, <span>N. Kurinij</span>, <span>M. D. Davis</span>, <span>A. Kassoff</span>, <span>J. Kassoff</span>, <span>J. Buehler</span>, <span>M. Eglow</span>, <span>S. Silverman</span>, <span>M. Mehu</span>, <span>S. Kieval</span>, <span>F. Kaufman</span>, <span>M. Mairs</span>, <span>B. Graig</span>, <span>A. Quattrocchi</span>, <span>D. Jones</span>, <span>J. Locatelli</span>, <span>A. Ruby</span>, <span>A. Capone</span>, <span>B. Garretson</span>, <span>T. Hassan</span>, <span>M. T. Trese</span>, <span>G. A. Williams</span>, <span>V. Regan</span>, <span>P. Manatrey</span>, <span>P. Streasick</span>, <span>L. Szydlowski</span>, <span>F. McIver</span>, <span>C. Bridges</span>, <span>C. Stanley</span>, <span>K. Cumming</span>, <span>B. Mitchell</span>, <span>J. Holloway</span>, <span>B. Lewis</span>, <span>M. Zajechowski</span>, <span>R. R. Margherio</span>, <span>M. S. Cox</span>, <span>J. C. Werner</span>, <span>R. Falk</span>, <span>P. Siedlak</span>, <span>C. Neubert</span>, <span>M. L. Klein</span>, <span>J. Stout</span>, <span>A. K. Lauer</span>, <span>C. Beardsley</span>, <span>H. Anderson</span>, <span>P. Wallace</span>, <span>G. Smith</span>, <span>S. Howard</span>, <span>R. F. Dreyer</span>, <span>C. Ma</span>, <span>R. G. Chenoweth</span>, <span>J. D. Zilis</span>, <span>A. O&rsquo;Malley</span>, <span>J. E. Robertson</span>, <span>D. J. Wilson</span>, <span>M. Johnson</span>, <span>P. Rice</span>, <span>H. Daniel</span>, <span>H. Crider</span>, <span>S. Parker</span>, <span>K. Sherman</span>, <span>D. F. Martin</span>, <span>T. M. Aaberg</span>, <span>G. Hubbard</span>, <span>E. Garcia</span>, <span>L. T. Curtis</span>, <span>A. DeLeon</span>, <span>B. Myles</span>, <span>H. Yi</span>, <span>A. Capone</span>, <span>M. Lambert</span>, <span>T. Meredith</span>, <span>T. M. Aaberg</span>, <span>P. Sternberg</span>, <span>D. Saperstein</span>, <span>J. I. Lim</span>, <span>B. Stribling</span>, <span>B. Ju</span>, <span>D. Armiger</span>, <span>J. Gilman</span>, <span>D. Jordan</span>, <span>S. Strittman</span>, <span>R. Swords</span>, <span>D. H. Orth</span>, <span>T. P. Flood</span>, <span>J. Civantos</span>, <span>S. deBustros</span>, <span>K. H. Packo</span>, <span>P. T. Merrill</span>, <span>J. A. Cohen</span>, <span>D. Chow</span>, <span>C. Figliulo</span>, <span>C. Morrison</span>, <span>D. A. Bryant</span>, <span>D. Doherty</span>, <span>M. McVicker</span>, <span>T. Drefcinski</span>, <span>J. M. Seddon</span>, <span>M. K. Pinnolis</span>, <span>M. Sachdeva</span>, <span>T. Taytsel</span>, <span>I. Burton</span>, <span>D. Walsh</span>, <span>C. Callahan</span>, <span>C. Evans</span>, <span>K. K. Snow</span>, <span>D. A. Jones-Devonish</span>, <span>V. D. Crouse</span>, <span>N. Rosenberg</span>, <span>N. Davis</span>, <span>J. Dubois-Moran</span>, <span>E. Y. Chew</span>, <span>K. Csaky</span>, <span>F. L. Ferris</span>, <span>K. H. Shimel</span>, <span>M. A. Woods</span>, <span>D. Cunningham</span>, <span>E. M. Kuehl</span>, <span>M. Palmer</span>, <span>G. Babilonia-Ayukawa</span>, <span>G. E. Foster</span>, <span>Y. J. Kim</span>, <span>I. J. Kivitz</span>, <span>D. Koutsandreas</span>, <span>A. LaReau</span>, <span>R. F. Mercer</span>, <span>R. Nashwinter</span>, <span>J. Rowan</span>, <span>G. Short</span>, <span>S. A. McCarthy</span>, <span>P. F. Ciatto</span>, <span>L. M. Ayres</span>, <span>L. Goodman</span>, <span>P. Lopez</span>, <span>C. Perry</span>, <span>A. Randalls</span>, <span>T. R. Friberg</span>, <span>A. W. Eller</span>, <span>M. B. Gorin</span>, <span>B. Mack</span>, <span>D. Y. Curtin</span>, <span>P. P. Ostroska</span>, <span>E. Fijewski</span>, <span>J. Alexander</span>, <span>S. Nixon</span>, <span>M. K. Paine</span>, <span>P. S. Corbin</span>, <span>J. Warnicki</span>, <span>S. B. Bressler</span>, <span>N. M. Bressler</span>, <span>G. Cassel</span>, <span>D. Finkelstein</span>, <span>M. Goldberg</span>, <span>J. A. Haller</span>, <span>L. Ratner</span>, <span>A. P. Schachat</span>, <span>S. H. Sherman</span>, <span>J. S. Sunness</span>, <span>S. Schenning</span>, <span>C. Sackett</span>, <span>D. Cain</span>, <span>D. Emmert</span>, <span>M. Herring</span>, <span>J. McDonald</span>, <span>R. Falk</span>, <span>S. Wheeler</span>, <span>M. Mcmillan</span>, <span>T. George</span>, <span>M. J. Elman</span>, <span>R. Ballinger</span>, <span>A. Betancourt</span>, <span>M. Herr</span>, <span>J. Lammlein</span>, <span>R. Z. Raden</span>, <span>R. Seff</span>, <span>M. Shuman</span>, <span>J. Starr</span>, <span>D. Firestone</span>, <span>M. Sloan</span>, <span>P. Sotirakos</span>, <span>T. Cain</span>, <span>T. Mathews</span>, <span>D. Glasser</span>, <span>D. Hirsch</span>, <span>D. Killingsworth</span>, <span>P. Kohlhepp</span>, <span>C. Ringrose</span>, <span>A. Carrigan</span>, <span>S. R. Chandra</span>, <span>J. L. Gottlieb</span>, <span>M. S. Ip</span>, <span>R. Klein</span>, <span>T. Nork</span>, <span>T. S. Stevens</span>, <span>B. A. Blodi</span>, <span>M. Altaweel</span>, <span>B. E. Klein</span>, <span>M. D. Davis</span>, <span>M. Olson</span>, <span>A. Skoldberg</span>, <span>E. Christianson</span>, <span>B. Soderling</span>, <span>J. R. Perry-Raymond</span>, <span>K. Burke</span>, <span>G. Knutson</span>, <span>J. Peterson</span>, <span>D. Krolnik</span>, <span>R. Harrison</span>, <span>G. Somers</span>, <span>F. L. Myers</span>, <span>I. Wallow</span>, <span>T. W. Olsen</span>, <span>G. Bresnik</span>, <span>G. De Venecia</span>, <span>T. Perkins</span>, <span>W. Walker</span>, <span>J. L. Miller</span>, <span>M. Blatz</span>, <span>M. Neider</span>, <span>H. D. Wabers</span>, <span>G. Weber</span>, <span>B. Amspaugh</span>, <span>J. Buechner</span>, <span>H. E. Lyngaas Myers</span>, <span>M. D. Davis</span>, <span>B. E. Klein</span>, <span>R. Klein</span>, <span>B. Blodi</span>, <span>R. Danis</span>, <span>L. Hubbard</span>, <span>M. Neider</span>, <span>P. Vargo</span>, <span>H. D. Wabers</span>, <span>J. Armstrong</span>, <span>W. Benz</span>, <span>K. L. Dohm</span>, <span>C. Fink</span>, <span>T. Harding</span>, <span>C. Hurtenbach</span>, <span>K. Lang</span>, <span>S. Reed</span>, <span>M. R. Fisher</span>, <span>R. Gangnon</span>, <span>L. Y. Lee</span>, <span>A. Carr</span>, <span>J. Baliker</span>, <span>L. Kastorff</span>, <span>N. Robinson</span>, <span>K. E. Glander</span>, <span>J. Surfus</span>, <span>S. Ansay</span>, <span>Y. L. Magli</span>, <span>D. Badal</span>, <span>S. Craanen</span>, <span>J. Elledge</span>, <span>B. Esser</span>, <span>P. L. Geithman</span>, <span>K. D. Miner</span>, <span>J. Reimers</span>, <span>M. Webster</span>, <span>C. Gai</span>, <span>W. King</span>, <span>K. Osterby</span>, <span>J. Onofrey</span>, <span>J. Brickbauer</span>, <span>R. L. Schleicher</span>, <span>D. T. Miller</span>, <span>A. L. Sowell</span>, <span>E. W. Gunter</span>, <span>B. A. Bowman</span>, <span>A. S. Lindblad</span>, <span>R. C. Milton</span>, <span>T. E. Clemons</span>, <span>G. Gensler</span>, <span>M. Rankin</span>, <span>A. Henning</span>, <span>C. Davis</span>, <span>G. Entler</span>, <span>W. McBee</span>, <span>E. Stine</span>, <span>V. Watson</span>, <span>S. H. Berlin</span>, <span>K. Thotapally</span>, <span>M. Jackson</span>, <span>K. Tomlin</span>, <span>S. Pallas</span>, <span>P. R. Scholl</span>, <span>S. A. Mengers</span>, <span>F. Ederer</span>, <span>R. Anand</span>, <span>K. Roberts</span>, <span>F. L. Ferris III</span>, <span>R. D. Sperduto</span>, <span>N. Kurinij</span>, <span>E. Y. Chew</span>, <span>J. P. SanGiovanni</span>

  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    Aug 2013
  </span>
  

  

  

  
  
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="https://www.aaojournal.org/article/S0161-6420%2813%2900036-5/fulltext" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/pmid-23582353/cite.bib">
  Cite
</button>















</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">OBJECTIVE:
To describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD). DESIGN:
Multicenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study. PARTICIPANTS:
We enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study. METHODS:
Participants were randomly assigned to antioxidants C, E, and β-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses. MAIN OUTCOME MEASURES:
Photographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (≥15 letters). RESULTS:
Comparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P&lt;0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53-0.83 and OR, 0.60; 95% CI, 0.47-0. 78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71-1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57-0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases. CONCLUSIONS:
Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Ophthalmology</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    
















  
  
    
  
  














  
  



  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/highlight.min.js" integrity="sha256-1zu+3BnLYV9LdiY85uXMzii3bdrkelyp37e0ZyTAQh0=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/languages/r.min.js"></script>
        
      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js" integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.0630fec5958cb075a5a38f042b3ddde6.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/privacy/">Privacy Policy</a>
    
    
       &middot; 
      <a href="/terms/">Terms</a>
    
  </p>
  

  <p class="powered-by">
    

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
